PD Dr. Dorota Lubgan

Department of Radiation Oncology

Comparison of dose calculation approaches and clinical dose–response in image-guided head&neck brachytherapy of the oral cavity (2025) Schaller S, Strnad V, Schweizer C, Lubgan D, Merten R, Fietkau R, Bert C, Karius A Journal article Pt-Au Nanoparticles in Combination with Near-Infrared-Based Hyperthermia Increase the Temperature and Impact on the Viability and Immune Phenotype of Human Hepatocellular Carcinoma Cells (2025) Szwed M, Jost T, Majka E, Gharibkandi NA, Majkowska-Pilip A, Frey B, Bilewicz A, et al. Journal article Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial (2025) Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, Croner RS, et al. Journal article Newly Synthesized Melphalan Analogs Induce DNA Damage and Mitotic Catastrophe in Hematological Malignant Cancer Cells (2022) Poczta A, Krzeczynski P, Ionov M, Rogalska A, Gaipl U, Marczak A, Lubgan D Journal article Permanent LDR prostate brachytherapy: Comprehensive characterization of seed-dynamics within the prostate on a seed-only level (2022) Karius A, Lotter M, Kreppner S, Schaller V, Lubgan D, Grigo J, Fietkau R, et al. Journal article Automatisation of catheter reconstruction in interstitial breast BT using electromagnetic tracking (2022) Dürrbeck C, Abu-Hossin N, Lotter M, Kreppner S, Lubgan D, Fietkau R, Strnad V, Bert C Conference contribution Low-dose-rate Prostate Brachytherapy: Characterization of Seeds Dynamics within the Prostate (2022) Karius A, Lotter M, Kreppner S, Lubgan D, Grigo J, Fietkau R, Strnad V, Bert C Conference contribution 12 x 6 Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma? (2021) Lubgan D, Semrau S, Lambrecht U, Gaipl U, Fietkau R Journal article 12 x 6 Gy stereotactic radiotherapy for lung tumours. Is there a difference in response between lung metastases and primary bronchial carcinoma? (2021) Lubgan D, Semrau S, Lambrecht U, Gaipl U, Fietkau R Conference contribution Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial (2020) Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, et al. Journal article